F5 sirna

F5 siRNA (Human)

Cat. Num. AAA8204863

• Gene Names: F5; FVL; PCCF; THPH2; RPRGL1
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: F5; F5 siRNA (Human); Coagulation factor V; Activated protein C cofactor; Proaccelerin. labile factor; F5 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: F5 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 2224

• Applicable Applications for F5 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human F5 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for F5 sirna

siRNA to inhibit F5 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 105990535
• NCBI GeneID: 2153
• NCBI Accession #: NP_000121.2
• NCBI GenBank Nucleotide #: NM_000130.4
• UniProt Accession #: P12259; Q14285; Q2EHR5; Q5R346; Q5R347; Q6UPU6; Q8WWQ6; A8K6E8
• Molecular Weight: 251,703 Da
• NCBI Official Full Name: coagulation factor V
• NCBI Official Synonym Full Names: coagulation factor V (proaccelerin, labile factor)
• NCBI Official Symbol: F5
• NCBI Official Synonym Symbols: FVL; PCCF; THPH2; RPRGL1
• NCBI Protein Information: coagulation factor V
• UniProt Protein Name: Coagulation factor V
• Protein Family: Coagulation factor
• UniProt Gene Name: F5
• UniProt Entry Name: FA5_HUMAN

NCBI Description

This gene encodes an essential cofactor of the blood coagulation cascade. This factor circulates in plasma, and is converted to the active form by the release of the activation peptide by thrombin during coagulation. This generates a heavy chain and a light chain which are held together by calcium ions. The activated protein is a cofactor that participates with activated coagulation factor X to activate prothrombin to thrombin. Defects in this gene result in either an autosomal recessive hemorrhagic diathesis or an autosomal dominant form of thrombophilia, which is known as activated protein C resistance. [provided by RefSeq, Oct 2008]

Uniprot Description

factor V: Central regulator of hemostasis. It serves as a critical cofactor for the prothrombinase activity of factor Xa that results in the activation of prothrombin to thrombin. Defects in F5 are the cause of factor V deficiency (FA5D); also known as Owren parahemophilia. It is an hemorrhagic diastesis. Defects in F5 are the cause of thrombophilia due to activated protein C resistance (THPH2). THPH2 is a hemostatic disorder due to defective degradation of factor Va by activated protein C. It is characterized by a poor anticoagulant response to activated protein C resulting in tendency to thrombosis. Defects in F5 are a cause of susceptibility to Budd- Chiari syndrome (BDCHS). A syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera. Defects in F5 may be a cause of susceptibility to ischemic stroke (ISCHSTR); also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors. Defects in F5 are associated with susceptibility to pregnancy loss, recurrent, type 1 (RPRGL1). RPRGL1 is a common complication of pregnancy, resulting in spontaneous abortion before the fetus has reached viability. The term includes all miscarriages from the time of conception until 24 weeks of gestation. Recurrent pregnancy loss is defined as 3 or more consecutive spontaneous abortions. Belongs to the multicopper oxidase family.

Protein type: Secreted, signal peptide; Protease; Secreted

Chromosomal Location of Human Ortholog: 1q23

Cellular Component: Golgi apparatus; extracellular space; membrane; endoplasmic reticulum; plasma membrane; extracellular region; vesicle

Molecular Function: protein binding; copper ion binding; serine-type endopeptidase activity

Biological Process: platelet activation; platelet degranulation; blood circulation; proteolysis; blood coagulation

Disease: Thrombophilia Due To Activated Protein C Resistance; Budd-chiari Syndrome; Pregnancy Loss, Recurrent, Susceptibility To, 1; Stroke, Ischemic; Factor V Deficiency